Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure
First Claim
1. A method of delivering a drug dosage from a drug dispenser to receptors of the central nervous system of a patient'"'"'s body to therapeutically treat one of pre-existing symptoms of heart failure (“
- HF”
) and pre-existing pathologies associated with HF, the method comprising the steps of;
surgically implanting a drug infusion catheter with a distal drug delivery portion disposed at a predetermined central nervous system site;
coupling a proximal end of the drug infusion catheter to a drug delivery pump;
monitoring the patient for at least one pre-existing of symptoms of HF and pre-existing pathologies associated with HF; and
in response to a positive detection of one pre-existing of HF and pre-existing pathologies associated with HF, operating the drug delivery pump to discharge a predetermined dosage of a sympatholytic cardiovascular agent to a central nervous system site effective to alleviate at least one of the pre-existing symptoms of HF and the pre-existing pathologies associated with HF.
1 Assignment
0 Petitions
Accused Products
Abstract
A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine.
-
Citations
37 Claims
-
1. A method of delivering a drug dosage from a drug dispenser to receptors of the central nervous system of a patient'"'"'s body to therapeutically treat one of pre-existing symptoms of heart failure (“
- HF”
) and pre-existing pathologies associated with HF, the method comprising the steps of;surgically implanting a drug infusion catheter with a distal drug delivery portion disposed at a predetermined central nervous system site; coupling a proximal end of the drug infusion catheter to a drug delivery pump; monitoring the patient for at least one pre-existing of symptoms of HF and pre-existing pathologies associated with HF; and in response to a positive detection of one pre-existing of HF and pre-existing pathologies associated with HF, operating the drug delivery pump to discharge a predetermined dosage of a sympatholytic cardiovascular agent to a central nervous system site effective to alleviate at least one of the pre-existing symptoms of HF and the pre-existing pathologies associated with HF. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
- HF”
Specification